Abstract

One glucagon-like peptide-1 (GLP-1) agonist, liraglutide (Saxenda), is approved for treating obesity. Now, another GLP-1 agonist, semaglutide (marketed

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call